AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase 2 study titled DESTINY-PanTumor02 to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) in treating selected HER2-expressing tumors. The study aims to demonstrate meaningful clinical activity and a favorable risk-benefit profile for T-DXd in various solid tumors, including bladder, biliary tract, cervical, endometrial, ovarian, pancreatic cancers, and rare tumors.
The intervention being tested is Trastuzumab Deruxtecan, a drug administered via intravenous infusion, designed to target and treat HER2-expressing tumors.
This interventional study is open-label and non-randomized, with a parallel assignment model. It primarily focuses on treatment, with no masking involved, allowing researchers to observe the direct effects of the drug on participants.
The study began on August 18, 2020, with an estimated completion date set for July 21, 2025. These dates are crucial as they mark the timeline for data collection and analysis, impacting the potential market release of the treatment.
This update could positively influence AstraZeneca’s stock performance by showcasing the company’s commitment to innovative cancer treatments. It may also affect investor sentiment positively, as successful outcomes could position AstraZeneca favorably against competitors in the oncology market.
The study is currently ongoing, with further details available on the ClinicalTrials portal.